HEADER OXIDOREDUCTASE 17-DEC-01 1KMV TITLE HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND (Z)-6-(2-[2,5- TITLE 2 DIMETHOXYPHENYL]ETHEN-1-YL)-2,4-DIAMINO-5-METHYLPYRIDO[2,3- TITLE 3 D]PYRIMIDINE (SRI-9662), A LIPOPHILIC ANTIFOLATE COMPND MOL_ID: 1; COMPND 2 MOLECULE: DIHYDROFOLATE REDUCTASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: DHFR; COMPND 5 EC: 1.5.1.3; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_CELLULAR_LOCATION: CYTOPLASM; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_VECTOR: PET11A; SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PDFR KEYWDS OXIDOREDUCTASE, ANTIPARASITIC DRUGS, REDUCTASE, LIPOPHILIC KEYWDS 2 ANTIFOLATES EXPDTA X-RAY DIFFRACTION AUTHOR A.E.KLON,A.HEROUX,L.J.ROSS,V.PATHAK,C.A.JOHNSON,J.R.PIPER,D.W.BORHANI REVDAT 5 03-APR-24 1KMV 1 REMARK REVDAT 4 14-FEB-24 1KMV 1 REMARK REVDAT 3 24-FEB-09 1KMV 1 VERSN REVDAT 2 01-APR-03 1KMV 1 JRNL REVDAT 1 10-JUL-02 1KMV 0 JRNL AUTH A.E.KLON,A.HEROUX,L.J.ROSS,V.PATHAK,C.A.JOHNSON,J.R.PIPER, JRNL AUTH 2 D.W.BORHANI JRNL TITL ATOMIC STRUCTURES OF HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED JRNL TITL 2 WITH NADPH AND TWO LIPOPHILIC ANTIFOLATES AT 1.09 A AND 1.05 JRNL TITL 3 A RESOLUTION. JRNL REF J.MOL.BIOL. V. 320 677 2002 JRNL REFN ISSN 0022-2836 JRNL PMID 12096917 JRNL DOI 10.1016/S0022-2836(02)00469-2 REMARK 2 REMARK 2 RESOLUTION. 1.05 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.05 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 97.5 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : 5% OF THE REFLECTIONS WERE REMARK 3 RANDOMLY SELECTED FOR THE REMARK 3 TEST SET. REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.130 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.181 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 4325 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 86271 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.123 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.173 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 3436 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 68227 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1471 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 82 REMARK 3 SOLVENT ATOMS : 338 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1843.1 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1412.0 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 17 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 17886 REMARK 3 NUMBER OF RESTRAINTS : 21912 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.017 REMARK 3 ANGLE DISTANCES (A) : 0.035 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.029 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.081 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.086 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.031 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.006 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.058 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.105 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER, J.MOL.BIOL.91(1973)201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT BEGAN WITH RIGID-BODY REMARK 3 MINIMIZATION (X-PLOR) USING THE COORDINATES AND REMARK 3 ISOTROPIC TEMPERATURE FACTORS OF HDHFR AND NADPH FROM THE REMARK 3 HDHFR/NADPH/SRI-9439 TERNARY COMPLEX (PDB ENTRY 1KMS), REMARK 3 WITH THE CIS PEPTIDE BONDS RESTRAINED. ALTERNATING REMARK 3 BETWEEN REFINEMENT IN X-PLOR AND MANUAL REBUILDING IN O REMARK 3 RESULTED IN A FREE R-FACTOR OF 23.9%. SRI-9662 WAS ADDED REMARK 3 AFTER ITS DENSITY BECAME APPARENT IN THE 2FO-FC AND FO-FC REMARK 3 MAPS. REFINEMENT CONTINUED WITH THE ADDITION OF RIDING REMARK 3 HYDROGEN ATOMS AND ANISOTROPIC TEMPERATURE FACTORS IN REMARK 3 REFMAC AND ARP, RESULTING IN A FREE R-FACTOR OF 19.6%. REMARK 3 MOST OF THE SIDE CHAINS WITH ALTERNATE CONFORMATIONS WERE REMARK 3 MODELED AT THIS POINT. REFINEMENT WAS COMPLETED USING REMARK 3 SHELXL. REFINEMENT OF THE ANISOTROPIC DISPLACEMENT REMARK 3 PARAMETERS, ADDITION OF RIDING HYDROGENS, AND REMOVAL OF REMARK 3 ALL RESTRAINTS ON THE PTERIDINE RING OF SRI-9662 RESULTED REMARK 3 IN A FREE R-FACTOR OF 18.1%. SEVERAL LARGE PEAKS OF REMARK 3 POSITIVE DIFFERENCE DENSITY WERE LOCATED IN THE NADPH REMARK 3 BINDING SITE, THE LARGEST BEING 0.7 A AWAY FROM THE C7N REMARK 3 CARBON ATOM, AND WERE ASSIGNED TO DMSO AT PARTIAL REMARK 3 OCCUPANCY. HOH 607, 608, AND 609 ARE LOCATED IN THE REMARK 3 NDP BINDING SITE, ARE PRESENT ONLY WHEN NDP IS NOT, AND ARE THUS REMARK 3 INCLUDED IN REMARK 3 ALTERNATE CONFORMATION B, ALONG WITH THE DMSO MOLECULE (NDP IS REMARK 3 MODELED AS ALTERNATE CONFORMATION A). REMARK 4 REMARK 4 1KMV COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-JAN-02. REMARK 100 THE DEPOSITION ID IS D_1000015122. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-JUN-98 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 8.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : NSLS REMARK 200 BEAMLINE : X25 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.90 REMARK 200 MONOCHROMATOR : SI (111) REMARK 200 OPTICS : PT-COATED MIRROR REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : BRANDEIS - B4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : CCP4 (SCALA) REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 86349 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.050 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.5 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.05300 REMARK 200 R SYM (I) : 0.05300 REMARK 200 FOR THE DATA SET : 9.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.05 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.09 REMARK 200 COMPLETENESS FOR SHELL (%) : 83.8 REMARK 200 DATA REDUNDANCY IN SHELL : 2.10 REMARK 200 R MERGE FOR SHELL (I) : 0.23100 REMARK 200 R SYM FOR SHELL (I) : 0.23100 REMARK 200 FOR SHELL : 2.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: UNPUBLISHED HUMAN DHFR STRUCTURE. REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.20 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE TERNARY COMPLEX OF DHFR WITH NADPH REMARK 280 AND SRI-9662 WAS FORMED BY MIXING HUMAN DHFR (20 MG/ML IN 25 MM REMARK 280 KPO4 (PH 7.0), 0.1 MM EDTA, AND 3 MM NAN3) WITH 60 MM NADPH, REMARK 280 FOLLOWED 15 MINUTES LATER BY 60 MM OF INHIBITOR IN DMSO (FINAL REMARK 280 CONCENTRATIONS OF 2 MM NADPH AND 2 MM INHIBITOR). THIS COMPLEX REMARK 280 SOLUTION WAS MIXED WITH AN EQUAL VOLUME OF PRECIPITANT REMARK 280 CONTAINING 24-33% PEG 4000, 0.2 M LI2SO4, 0.1 M TRIS CL (PH 7.9- REMARK 280 8.4), 5% GLYCEROL, AND EQUILIBRATED WITH THE PRECIPITANT BY REMARK 280 HANGING DROP VAPOR DIFFUSION AT 277 K. THE CRYSTAL GREW IN ABOUT REMARK 280 3 WEEKS. THE CRYSTAL WAS FLASH-COOLED DIRECTLY IN LIQUID REMARK 280 NITROGEN AFTER HARVESTING INTO MOTHER LIQUOR CONTAINING 10% REMARK 280 GLYCEROL., PH 8.00, VAPOR DIFFUSION, HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 20.65000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 41.34000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 27.49500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 41.34000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 20.65000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 27.49500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ASP A 21 CG OD1 OD2 REMARK 470 LYS A 63 NZ REMARK 470 LYS A 68 CE REMARK 470 ARG A 77 CD NE NH1 NH2 REMARK 470 GLU A 78 CG CD OE1 OE2 REMARK 470 LYS A 98 NZ REMARK 470 GLU A 101 CD OE1 OE2 REMARK 470 GLU A 123 CD OE1 OE2 REMARK 470 GLU A 143 CD OE1 OE2 REMARK 470 ASP A 186 CA C O CB CG OD1 OD2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 28 NE - CZ - NH1 ANGL. DEV. = 6.9 DEGREES REMARK 500 ARG A 28 NE - CZ - NH2 ANGL. DEV. = -3.8 DEGREES REMARK 500 ARG A 32 NE - CZ - NH2 ANGL. DEV. = -3.7 DEGREES REMARK 500 MET A 37 CG - SD - CE ANGL. DEV. = -11.3 DEGREES REMARK 500 ARG A 65 NE - CZ - NH1 ANGL. DEV. = 3.2 DEGREES REMARK 500 ASP A 95 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP A 110 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 110 -94.41 -100.68 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 204 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE LII A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NDP A 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE DMS A 203 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1KMS RELATED DB: PDB REMARK 900 HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND 6- ([5- REMARK 900 QUINOLYLAMINO]METHYL)-2,4-DIAMINO-5-METHYLPYRIDO[2,3- D]PYRIMIDINE REMARK 900 (SRI-9439), A LIPOPHILIC ANTIFOLATE DBREF 1KMV A 1 186 UNP P00374 DYR_HUMAN 1 186 SEQRES 1 A 186 VAL GLY SER LEU ASN CYS ILE VAL ALA VAL SER GLN ASN SEQRES 2 A 186 MET GLY ILE GLY LYS ASN GLY ASP LEU PRO TRP PRO PRO SEQRES 3 A 186 LEU ARG ASN GLU PHE ARG TYR PHE GLN ARG MET THR THR SEQRES 4 A 186 THR SER SER VAL GLU GLY LYS GLN ASN LEU VAL ILE MET SEQRES 5 A 186 GLY LYS LYS THR TRP PHE SER ILE PRO GLU LYS ASN ARG SEQRES 6 A 186 PRO LEU LYS GLY ARG ILE ASN LEU VAL LEU SER ARG GLU SEQRES 7 A 186 LEU LYS GLU PRO PRO GLN GLY ALA HIS PHE LEU SER ARG SEQRES 8 A 186 SER LEU ASP ASP ALA LEU LYS LEU THR GLU GLN PRO GLU SEQRES 9 A 186 LEU ALA ASN LYS VAL ASP MET VAL TRP ILE VAL GLY GLY SEQRES 10 A 186 SER SER VAL TYR LYS GLU ALA MET ASN HIS PRO GLY HIS SEQRES 11 A 186 LEU LYS LEU PHE VAL THR ARG ILE MET GLN ASP PHE GLU SEQRES 12 A 186 SER ASP THR PHE PHE PRO GLU ILE ASP LEU GLU LYS TYR SEQRES 13 A 186 LYS LEU LEU PRO GLU TYR PRO GLY VAL LEU SER ASP VAL SEQRES 14 A 186 GLN GLU GLU LYS GLY ILE LYS TYR LYS PHE GLU VAL TYR SEQRES 15 A 186 GLU LYS ASN ASP HET SO4 A 204 5 HET LII A 201 25 HET NDP A 202 48 HET DMS A 203 4 HETNAM SO4 SULFATE ION HETNAM LII (Z)-6-(2-[2,5-DIMETHOXYPHENYL]ETHEN-1-YL)-2,4-DIAMINO- HETNAM 2 LII 5-METHYLPYRIDO[2,3-D]PYRIMIDINE HETNAM NDP NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE HETNAM 2 NDP PHOSPHATE HETNAM DMS DIMETHYL SULFOXIDE HETSYN LII SRI-9662 FORMUL 2 SO4 O4 S 2- FORMUL 3 LII C18 H19 N5 O2 FORMUL 4 NDP C21 H30 N7 O17 P3 FORMUL 5 DMS C2 H6 O S FORMUL 6 HOH *338(H2 O) HELIX 1 1 LEU A 27 THR A 40 1 14 HELIX 2 2 LYS A 54 ILE A 60 1 7 HELIX 3 3 PRO A 61 ARG A 65 5 5 HELIX 4 4 SER A 92 GLN A 102 1 11 HELIX 5 5 GLY A 117 ASN A 126 1 10 SHEET 1 A 8 PHE A 88 SER A 90 0 SHEET 2 A 8 ILE A 71 LEU A 75 1 N VAL A 74 O PHE A 88 SHEET 3 A 8 GLN A 47 GLY A 53 1 N VAL A 50 O ILE A 71 SHEET 4 A 8 VAL A 109 ILE A 114 1 O TRP A 113 N LEU A 49 SHEET 5 A 8 LEU A 4 VAL A 10 1 N ASN A 5 O ILE A 114 SHEET 6 A 8 LEU A 131 ILE A 138 1 O PHE A 134 N CYS A 6 SHEET 7 A 8 ILE A 175 LYS A 184 -1 O TYR A 182 N LEU A 133 SHEET 8 A 8 LYS A 157 LEU A 158 -1 N LYS A 157 O GLU A 183 SHEET 1 B 8 PHE A 88 SER A 90 0 SHEET 2 B 8 ILE A 71 LEU A 75 1 N VAL A 74 O PHE A 88 SHEET 3 B 8 GLN A 47 GLY A 53 1 N VAL A 50 O ILE A 71 SHEET 4 B 8 VAL A 109 ILE A 114 1 O TRP A 113 N LEU A 49 SHEET 5 B 8 LEU A 4 VAL A 10 1 N ASN A 5 O ILE A 114 SHEET 6 B 8 LEU A 131 ILE A 138 1 O PHE A 134 N CYS A 6 SHEET 7 B 8 ILE A 175 LYS A 184 -1 O TYR A 182 N LEU A 133 SHEET 8 B 8 GLN A 170 GLU A 172 -1 N GLN A 170 O TYR A 177 SHEET 1 C 2 GLY A 15 GLY A 17 0 SHEET 2 C 2 THR A 146 PHE A 147 -1 N THR A 146 O GLY A 17 CISPEP 1 ARG A 65 PRO A 66 0 -9.10 CISPEP 2 GLY A 116 GLY A 117 0 6.07 SITE 1 AC1 5 ARG A 28 LYS A 68 GLY A 69 HOH A 370 SITE 2 AC1 5 HOH A 590 SITE 1 AC2 15 ILE A 7 VAL A 8 ALA A 9 GLU A 30 SITE 2 AC2 15 PHE A 31 PHE A 34 SER A 59 PRO A 61 SITE 3 AC2 15 VAL A 115 TYR A 121 NDP A 202 DMS A 203 SITE 4 AC2 15 HOH A 302 HOH A 441 HOH A 627 SITE 1 AC3 38 VAL A 8 ALA A 9 ILE A 16 GLY A 17 SITE 2 AC3 38 LYS A 18 GLY A 20 ASP A 21 LEU A 22 SITE 3 AC3 38 TRP A 24 GLY A 53 LYS A 54 LYS A 55 SITE 4 AC3 38 THR A 56 SER A 59 LEU A 75 SER A 76 SITE 5 AC3 38 ARG A 77 GLU A 78 ARG A 91 VAL A 115 SITE 6 AC3 38 GLY A 117 SER A 118 SER A 119 VAL A 120 SITE 7 AC3 38 TYR A 121 GLU A 123 THR A 146 LII A 201 SITE 8 AC3 38 HOH A 317 HOH A 339 HOH A 395 HOH A 549 SITE 9 AC3 38 HOH A 596 HOH A 603 HOH A 604 HOH A 607 SITE 10 AC3 38 HOH A 608 HOH A 609 SITE 1 AC4 7 VAL A 8 ALA A 9 ILE A 16 LEU A 22 SITE 2 AC4 7 VAL A 115 TYR A 121 LII A 201 CRYST1 41.300 54.990 82.680 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.024213 0.000000 0.000000 0.00000 SCALE2 0.000000 0.018185 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012095 0.00000